<DOC>
	<DOCNO>NCT00095589</DOCNO>
	<brief_summary>RATIONALE : New diagnostic procedure microsatellite analysis sediment urine may improve ability detect bladder cancer without invasive procedure . PURPOSE : Diagnostic trial study effectiveness microsatellite analysis sediment urine detect bladder cancer healthy participant , participant genitourinary condition require cystoscopy , patient bladder cancer .</brief_summary>
	<brief_title>Microsatellite Analysis Urinary Sediment Detecting Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare sensitivity specificity microsatellite analysis ( MSA ) urine sediment cystoscopy urine cytology detect bladder cancer participant undergo cystoscopy . Secondary - Determine temporal performance characteristic MSA urine sediment participant . - Determine 15 individual marker combination marker make MSA test predictive presence bladder cancer participant . OUTLINE : This single-blind , multicenter , cohort study . Urine blood specimen collect participant baseline . Urine specimen examine use microsatellite analysis , urine cytology , urinalysis . Patients group 2 3 also undergo cystoscopy baseline . Patients group 3 undergo cystoscopy , upper tract imaging ( e.g. , abdominal CT scan ) , microsatellite analysis , urine cytology , urinalysis every 3 month 2 year absence progressive disease . Microsatellite analysis , identifies loss heterozygosity use polymerase chain reaction technique , conduct 15 marker : D4S243 , D21S1245 , FGA , D17S695 , D16S476 , D9S171 , IFN-A , D20S48 , D13S802 , D17S654 , D16S310 , THO1 , D9S162 , D9S747 , MBP . PROJECTED ACCRUAL : A total 500 participant ( 100 group 1 2 300 group 3 ) accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Group 1 ( healthy volunteer ) : No prior concurrent urologic disease device No genitourinary ( GU ) complaint , include urgency frequency urination Normal urinalysis urine cytology Never smoke cigarette regularly ( i.e. , ≥ 1 cigarette/day ≥ 1 year ) No suspected exposure environmental bladder carcinogen &gt; 1 year , include , limited , follow occupation exposure : Aluminum industry Aromatic amine Coal gasification Coal tar pitch Coke plant Dye industry Leather industry Machinist Painter Rubber industry Truck , bus , taxi driver Group 2 ( participant condition ( ) lead falsepositive urinary bladder cancer screen study ) : GU complaint require cystoscopy No current GU malignancy At least 1 follow condition : Benign prostatic hypertrophy ( International Prostate Symptom Score &gt; 12 ) Foreign body ( stone , stent , catheter ) Hematuria ( gross microscopic ) GU infection ( e.g. , prostatitis , urinary tract infection , pyelonephritis , urethritis ) within past 3 month complete treatment No sign infection time study participation Group 3 ( superficial bladder cancer patient ) : Histologically confirm superficial bladder urothelial malignancy Primary recurrent disease No nontransitional cell carcinoma bladder , upper tract tumor , muscleinvasive tumor , superficial disease local therapy appropriate PATIENT CHARACTERISTICS : Age Over 40 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal See Disease Characteristics Other No prior cancer except nonmelanoma dermatologic malignancy Prior bladder cancer allow group 3 patient PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Prior intravesical therapy bladder cancer allow group 3 patient Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>